Skip to main content
. Author manuscript; available in PMC: 2011 Jun 15.
Published in final edited form as: Cancer Res. 2010 Oct 20;70(24):10351–10361. doi: 10.1158/0008-5472.CAN-10-0740

Figure 6. LDHA is a promising therapeutic target for neuroblastoma patients.

Figure 6

(A) Relative expression of LDHA in primary neuroblastoma tumors. LDHA levels in fetal brain were used as a control. Tumor numbers: low risk group (28), intermediate (21), MYCN single-copy, high risk (32) and MYCN amplified, high risk (20).

(B) Depletion of LDHA expression profoundly inhibits the proliferation of MYCN amplified neuroblastoma cells. The LDHA protein is indicated by arrowhead. *p< 0.01.

(C) Depletion of LDHA expression inhibits the tumorigenic capacity of Kelly cells (8 tumors were analyzed in each group).

(D) A model depicting N-Myc and HIF-1α cooperation in neuroblastoma tumor progression. See text for details.